On Dec. 17, 2015, Merck announced that the U.S. Food and Drug Administration (FDA) approved Bridion® (sugammadex) Injection 100 mg/mL (equivalent to 108.8 mg/mL sugammadex sodium) for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. The resources below provide CRNAs references and documents to support integration of sugammadex into practice.


Prescribing Information

AANA Practice Considerations


Visit AANALearn for professional development and continuing education opportunities:

  • AANA Journal Course No. 35, Part 6: Residual Neuromuscular Blockade 
  • New Technological Modalities in Anesthesia
  • Monitoring and Reversing Neuromuscular Block in the New Millennium 
  • Advanced Monitoring of Neuromuscular Block: State of the Art Assessment using Qualitative and Quantitative Measures

Literature References*

*Not an exhaustive literature list. For additional articles, visit the PubMed website.


​​​The resources on this page may incorporate or summarize views, guidelines, or recommendations of third parties. Such material is assembled and presented in good faith, but does not necessarily reflect the views of the AANA. Links to third-party websites are inserted for informational purposes and do not constitute endorsement of the material on those sites, or of any associated organization.

Contraceptive FAQ

Patients using hormonal contraceptives must use an additional, non-hormonal method of contraception for the next 7 days following sugammadex administration.